Abstract
Body surface area (BSA) was introduced intomedical oncology in order to derive a safestarting dose for phase I studies ofanticancer drugs from preclinical animaltoxicology data. It is not clear however,as to why dosing by BSA was extended to theroutine dosing of antineoplastic agents.Several formulas exist to estimate BSA, butthe formula derived by DuBois and DuBois isthe one used in adult medical oncology. This formula was derived based on data fromonly nine patients; subsequent attempts tovalidate the formula have found the DuBoisformula to either over or underestimate theactual determined BSA. While cardiacoutput does correlate with BSA, therelationship between BSA and otherphysiologic measures relevant for drugmetabolism and disposition, such as, renaland hepatic function, is weak ornonexistent. Further only epirubicin,etoposide, and carboplatin have beenstudied to determine if dosing by BSA wouldreduce interpatient variability, and noneof these drugs were found to havesignificant relationships between theirpharmacokinetics and BSA. Future clinicaltrials of new agents should not presumethat dosing based on BSA reducesinterpatient variability. Studies shouldexamine the role, if any, BSA has in dosingnew chemotherapeutic agents in initialphase I studies.
Similar content being viewed by others
References
Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Research 18: 853–856, 1958
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4): 219–244, 1966
DuBois D, DuBois E: A Formula to estimate the approximate surface area if height and weight be known. Arch Internal Med 17: 863–871, 1916
Mitchell D, Strydom NB, Graan CHv, Walt WHvd: Human surface area: comparison of the Du Bois formula with direct photometric measurement. Pflugers Arch 325(2): 188–190, 1971
Gehan EA, George SL: Estimation of human body surface area from height and weight. Cancer Chemother Rep 54(4): 225–235, 1970
Crawford J, Terry M, Rourke G: Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 5: 783–790, 1950
Kleiber M: Body size and metabolism. Hilgardia 6: 315–333, 1932
Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE: Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23(10): 1110–1116, 1995
Nawaratne S, Brien JE, Seeman E, Fabiny R, Zalcberg J, Cosolo W, Angus P, Morgan DJ: Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 46(5): 447–452, 1998
Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L: Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 6(5): 389–396, 1981
Swift CG, Homeida M, Halliwell M, Roberts CJ: Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 14(2): 149–152, 1978
Pirttiaho H: Liver size in evaluating drug metabolizing capacity in man. Int J Clin Pharmacol Biopharm 17(6): 271–276, 1979
Roberts CJ, Jackson L, Halliwell M, Branch RA: The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol 3(5): 907–913, 1976
Harvey AM: Classics in clinical science: the concept of renal clearance. Am J Med 68(1): 6–8, 1980
Cullen G, Nelson W, Holmes F: Studies of kidney function in children. J Clin Invest 14: 563–574, 1935
McIntosh J, Moller E, Slyke DV: The influence of body size on urea output. J Clin Invest 6(3): 467–483, 1928
Holten C: The dependence of the normal kidney function on the size of the body. Acta Paediatric 12: 251–267, 1932
Wesson L: Physiology of the Human Kidney New York. Grune and Stratton, 1969
Martin L, Chatelut E, Boneu A, Rostaing L, Roussilhes C, Caselles O, Canal P: Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer 85(7): 631–636, 1998
Gibson J, Evans W: Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in ninety normal humans. Clin Invest 16: 317–328, 1937
Boer P: Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 247(4 Pt 2): F632–F636, 1984
Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB: A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24(2): 153–172, 1996
de Simone G, Devereux RB, Daniels SR, Mureddu G, Roman MJ, Kimball TR, Greco R, Witt S, Contaldo F: Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 95(7): 1837–1843, 1997
Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner MA: Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45(3): 226–233, 1989
Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA: Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 45(4): 340–347, 1989
Rowinsky EK, Ettinger DS, Grochow LB, Brundrett RB, Cates AE, Donehower RC: Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. J Clin Oncol 4(12): 1835–1844, 1986
Grochow LB, Baraldi C, Noe D: Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82(4): 323–325, 1990
Cosolo WC, Morgan DJ, Seeman E, Zimet AS, McKendrick JJ, Zalcberg JR: Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs 5(3): 293–297, 1994
Dobbs NA, Twelves CJ: What is the effect of adjusting epirubicin doses for body surface area? Br J Cancer 78(5): 662–666, 1998
Gurney HP, Ackland S, Gebski V, Farrell G: Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation [see comments]. J Clin Oncol 16(7): 2299–2304, 1998
Alberts DS, Dorr RT: New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 3(1): 15–34, 1998
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR: Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12Suppl A: 51–57, 1985
Newell D, Calvert A, O'Reilly S, Burnell M, Gumbrell L, Boxall F, Gore M, Wiltshaw E: Prospective validation of a simple formula for determining carboplatin dosage. Brit J Cancer 56: 233, 1987
Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J:Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum( II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 45(12 Pt 1): 6502–6506, 1985
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function [see comments]. J Clin Oncol 7(11): 1748–1756, 1989
Piotrovsky VK, Huang ML, Van Peer A, Langenaecken C: Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Cancer Chemother Pharmacol 42(3): 221–228, 1998
Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F: Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9(8): 1480–1486, 1991
Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Houin G, Bugat R, Canal P: Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41(2): 125–132, 1998
Gurney H: Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14(9): 2590–2611, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sawyer, M., Ratain, M.J. Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing. Invest New Drugs 19, 171–177 (2001). https://doi.org/10.1023/A:1010639201787
Issue Date:
DOI: https://doi.org/10.1023/A:1010639201787